[The treatment with hepatoprotectors of patients with chronic liver diseases].
Hepatoprotectors were used in 89 patients with chronic liver diseases from 1 to 6 months. A positive clinico-biochemical and immunological effect, namely, increase of the T-lymphocyte count, normalization of the ratio of immunoregulator cells, reduction of the antibody-dependent cellular toxicity, level of circulating immune complexes, immunoglobulins. Patients with chronic persisting hepatitis showed a stable remission from 6 to 12 months. Despite prolonged treatment, patients with active chronic hepatitis and liver cirrhosis developed exacerbation of the disease that was in 2/3 of patients caused by an increase of deficit of theophyllin-sensitive lymphocytes-suppressors and in 1/3 by K-cell deficit. The necessity is emphasized of interrupted treatment with hepatoprotectors for not less that 2-3 months alternating hepatoprotectors with immunomodulators.
O I
OI
Iakhontova
O P
OP
Dudanova
D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D002908:Chronic Disease; D004341:Drug Evaluation; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D008099:Liver / Q000187:drug effects*; D008107:Liver Diseases / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D012074:Remission Induction; D013997:Time Factors
Lechenie gepatoprotektorami bol'nykh khronicheskimi zabolevaniiami pecheni.